News
Glaucoma therapy Roclanda launched by Santen
The therapy is a fixed-dose combination (FDC) of both netarsudil and latanoprost, and is a novel Rho-kinase (ROCK) inhibitor, which reduces intraocular pressure (IOP). The treatments also target trabecular meshwork (TM) dysfunction.